Chinese herbal medicine (JianPi-BuShen) and completion rate of adjuvant chemotherapy for patients with stage II and III colon cancer: A randomized clinical trial

• Published in: European journal of cancer (1990) Vol. 213; p. 115109
• Main Authors: Sun, Lingyun, Xu, Yun, Chen, Nan, Zhang, Chunze, Wu, Aiwen, Wang, Huaqing, Fei, Yutong, Shu, Peng, Diao, Dechang, Cheng, Jianping, Chu, Yuping, Liu, Tianshu, Wang, Wei, Yuan, Ye, Zeng, Baozhu, Cao, Yang, Cang, Shundong, Cao, Huijuan, Zhang, Tong, Zheng, Yang, Wu, Cun’en, Liu, Shaoyong, He, Bin, Yan, Yunzi, Yan, Shaohua, Wu, Na, Ning, Chunhui, Peng, Rongyan, Epstein, Andrew S., Cytryn, Samuel, Mao, Jun J., Yang, Yufei
• Format: Journal Article
• Language: English
• Published: Elsevier Ltd 01.12.2024
• Subjects: Adjuvant chemotherapy; Colon cancer; Completion rate; Randomized controlled trial; Relative dose intensity; Traditional Chinese herbal medicine; Completion rate; Adjuvant chemotherapy; Colon cancer; Randomized controlled trial; Traditional Chinese herbal medicine; Relative dose intensity
• ISSN: 0959-8049
• DOI: 10.1016/j.ejca.2024.115109

Many cancer patients express interest in using herbal medicine during chemotherapy, but little is known about its benefits and risks. This study aimed to evaluate the effects of the Chinese herbal medicine JianPi-BuShen formula (JPBS) on adjuvant chemotherapy completion in colon cancer patients. This multi-center, phase III, randomized, placebo-controlled trial included patients with stage II (high risk for recurrence) and stage III colon cancer following surgery, planning to receive CAPOX (capecitabine and oxaliplatin) chemotherapy. Patients were randomized 1:1 to receive either JPBS or a placebo. The primary outcome was the completion rate of planned chemotherapy cycles. Secondary outcomes included relative dose intensity (RDI), chemotherapy-induced toxicities, quality of life (measured by the Edmonton Symptom Assessment System - ESAS), adverse events (AEs), and serious AEs (SAEs). Predefined subgroup analyses were performed by age (>65/≤65) and TNM stage (II/III). A total of 376 participants were analyzed, with a median age of 60.3 years; 56.9 % were male, and 67.6 % had stage III disease. Chemotherapy completion was significantly higher in the JPBS group than in the placebo group (63.0 % vs. 47.6 %, P = 0.003). Oxaliplatin RDI was also higher in the JPBS group (P = 0.049). Subgroup analyses showed JPBS significantly improved completion rates for stage II patients (73.0 % vs. 42.4 %, P = 0.001) and younger patients (66.9 % vs. 48.8 %, P = 0.004). JPBS reduced grade ≥ 2 vomiting (3.8 % vs. 6.4 %, P = 0.007) but increased grade ≥ 2 thrombocytopenia (16.2 % vs. 12.4 %, P = 0.012). Quality of life improved in stage II and younger patients. JPBS improved chemotherapy completion rates in stage II and younger colon cancer patients without compromising tolerability. Further research is needed to explore its mechanisms and long-term effects. •Our RCT evaluated herbal medicine’s effect and safety for colon cancer chemotherapy.•JPBS can improve adjuvant chemotherapy completion rate by 15.4 % versus placebo.•The JPBS arm experienced 2.6 % less incidence of grade ≥ 2 vomiting than placebo arm.•Stage II and age ≤ 65 patient subgroups experienced greater benefits from JPBS.•No other differences were observed in AEs and SAEs between the arms.